Abstract: Provided are oral dosage forms that contain carbinoxamine in an immediate release format, and pseudoephedrine in a prolonged release format. The biphasic oral dosage forms may also contain other active ingredients in combination with carbinoxamine, including other decongestants, antitussives, analgesics and expectorants.

Abstract: A method for treating or ameliorating mucocutaneous or ocular toxicities or side effects resulting from molecular targeted therapy, including administering to a subject in need thereof a pharmaceutical composition which contains a therapeutically effective amount of a histone deacetylase (HDAC) inhibitor, wherein the mucocutaneous or ocular toxicities or side effects result from molecular targeted therapy.

Abstract: A method for preventing, treating, or ameliorating pruritus caused by skin, mucosa, or systemic disorder. The method comprises administering to a subject with pruritus or topically applying to an affected area with pruritus an effective amount of a formulation consisting essentially of a phenylbutyric acid or short-chain fatty acid derivative and a pharmaceutically acceptable carrier, salt or solvate thereof.

Abstract: Disclosed are a composition and a method for treating skin disorders, including rosacea, pityriasis rosea, erythema, rhinophyma, and rosacea-associated disorders including pimples, papules, pustules, and telangiectasia.

Abstract: Provided are oral dosage forms that contain carbinoxamine in an immediate release format, and pseudoephedrine in a prolonged release format. The biphasic oral dosage forms may also contain other active ingredients in combination with carbinoxamine, including other decongestants, antitussives, analgesics and expectorants.

Abstract: A method for treating or ameliorating mucocutaneous, ocular toxicities, or side effects induced by blocking cellular growth and survival signal transduction pathways. The method comprises administering to a subject in need thereof an effective amount of a histone deacetylase inhibitor and a pharmaceutically acceptable carrier, salt or solvate thereof, wherein the cell growth and survival signal transduction pathways are blocked by an antibody targeted therapy agent, antibody fragment, targeted small-molecule chemical compound, low-molecular-weight tyrosine kinase inhibitor, peptide mimetic, anti-sense oligonucleotide (DNA and/or RNA), or ribozyme.

Abstract: Disclosed are compositions and methods for skincare, e.g., reducing skin wrinkles and for treating skin disorders.

Abstract: Disclosed are a composition and a method for treating skin disorders, including rosacea, pityriasis rosea, erythema, rhinophyma, and rosacea-associated disorders including pimples, papules, pustules, and telangiectasia.

Abstract: Disclosed are compositions and methods for skincare, e.g., reducing skin wrinkles and for treating skin disorders.

Abstract: Provided are oral dosage forms that contain carbinoxamine in an immediate release format, and pseudoephedrine in a prolonged release format. The biphasic oral dosage forms may also contain other active ingredients in combination with carbinoxamine, including other decongestants, antitussives, analgesics and expectorants.

Abstract: A method for preventing, treating, or ameliorating pruritus caused by skin, mucosa, or systemic disorder. The method comprises administering to a subject with pruritus or topically applying to an affected area with pruritus an effective amount of a formulation consisting essentially of a phenylbutyric acid or short-chain fatty acid derivative and a pharmaceutically acceptable carrier, salt or solvate thereof.

Abstract: The present invention is directed to methods and compositions of treating or preventing epithelial lining tissue damage from dermatitis or mucositis induced by radiation exposure and/or chemotherapy, by applying to skin, mucosa or other tissues of the body an amount of a therapeutic composition which comprises a histone deacetylase inhibitor formulated with at least one pharmaceutically acceptable biocompatible polymer or carrier, or pharmaceutically acceptable salts in an amount sufficient to delay onset or decrease severity of the signs and symptoms of dermatitis and mucositis in cancer therapy. Such therapeutic compositions have the advantage of prolonged retention and sustained action of the histone deacetylase inhibitor in the skin, mucosa or other tissues of the body. The invention is also directed to treatment and prevention of gastrointestinal distress and cancer-related fatigue syndrome that are associated with mucositis in cancer therapy.

Abstract: A composition and method for treating and/or preventing acute and chronic gastrointestinal distress including nausea, vomiting, lactose intolerance, obstructive symptoms, diarrhea, mucositis, bleeding, weight loss, and malnutrition in a subject who is immunocompromised or receives a planned course of chemotherapy and/or radiotherapy. The method comprises administering a histone deacetylase inhibitor or in conjunction with a second agent to the subject. A composition and method using a histone deacetylase inhibitor for protecting normal tissues from chemotherapy and/or radiotherapy-induced injuries without the risk of tumor protection in cancer therapy is also provided. It is further provided a composition and method for treating and/or preventing cachexia, cancer-related fatigue, or chronic fatigue syndrome.